




Patent Application  
Attorney Docket No. PC28017

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 24th day of May 2004.

By \_\_\_\_\_

  
Andrea E. Dorigo

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Lee et al.

APPLICATION NO.: 10/626,275 : Examiner:

FILING DATE: July 25, 2002 : Group Art Unit: 1614

TITLE: PRAMIPEXOLE ONCE-DAILY  
DOSAGE FORM

MAIL STOP DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO-FB-A820 form is not intended to represent or imply that these references are prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.



Patent Application  
Attorney Docket No. PC28017

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "AED".

Andrea E. Dorigo  
Attorney for Applicant(s)  
Reg. No. 47,532

Date: May 24, 2004

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-1898



MAY 27 2004

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>									ATTY. DOCKET NO. PC28017	SERIAL NO. 10/626,275							
									APPLICANT Lee et al.								
									FILING DATE July 25, 2002								
<b>U.S. PATENT DOCUMENTS</b>																	
EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE			
		6	1	9	7	3	3	9	3/6/01	Ju, Tzu-chi Robert	424	468					
		5	4	5	8	8	8	7	10/17/95	Chen et al.	424	464					
		5	6	5	6	2	9	6	8/12/97	Khan et al.	424	473					
		2	8	8	7	4	4	0	5/19/59	Greminger et al.	167	82					
<b>FOREIGN PATENT DOCUMENTS</b>																	
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
		0	9	3	3	0	7	9	1/26/99	EPC	A61K	C08B	YES NO				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>																	
			Physicians' Desk Reference 57th edition (2003), 2768-2772														
			Hiestand & Smith (1984), Powder Technology 38, 145-159														
			Hiestand & Smith (1991), International Journal of Pharmaceutics 67, 231-246														
EXAMINER				DATE CONSIDERED													
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>																	

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE